New consultation: CRG actions April 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the April 2024 CRG meeting. Actions in this consultation include:

  • Lamotrigine tablets – green specialist advice for bipolar disorder
  • Doxylamine / pyridoxine for nausea and vomiting in pregnancy – removed from grey list and made a first choice option alongside cyclizine and prochlorperazine
  • Levemir InnoLet and Insulatard InnoLet – remove from formulary following discontinuation of the products
  • Buprenorphine prolonged release solution for injection (Buvidal) – add to formulary as alternative to methadone and oral buprenorphine
  • Fluocinolone intravitreal implant – RED
  • Dupilumab for prurigo nodularis – DNP
  • Etrasimod for ulcerative colitis – RED
  • Ritlecitinib for alopecia areata – RED
  • Satralizumab for neuromyelitis optica spectrum disorders – DNP
  • Sebelipase alfa for lysosomal acid lipase deficiency – DNP

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 24th May 2024. To take part, visit the consultations page.


New consultation: CRG actions March 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the March 2024 CRG meeting. Actions in this consultation include:

  • Doxazosin 8mg immediate-release tablets – DNP
  • Atropine 1% eye drops and minims for hypersalivation – GREEN (following specialist advice)
  • Paliperidone palmitate 700mg & 1000mg prolonged-release suspension for injection – add to formulary as AMBER (see also separate consultation on updated shared care protocol)
  • Add belumosudil as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 28th March 2024. To take part, visit the consultations page.


New consultation: CRG actions February 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their February 2024 meeting. Actions in this consultation include:

  • Riluzole 50mg orodispersible tablets added as AMBER
  • Diclofenac 50mg tablets made 3rd line choice, after ibuprofen and naproxen
  • Sebeliplase alfa added as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 28th March 2024. To take part, visit the consultations page.


Consultation: actions from September 2023 CRG meeting

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their September 2023 meeting. Actions in this consultation include:

  • Tadalafil 5mg once daily – remove from DNP list and assign GREEN RAG status
  • Herbal treatments – DNP listing amended to “herbal treatments and other natural products”, in line with NHS England guidance
  • Cipaglucosidase alfa – add to formulary as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Friday 27th October 2023. To take part, visit the consultations page.


Consultation: actions from August 2023 CRG meeting

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their August 2023 meeting. Actions in this consultation include:

  • Sodium chloride 5% eye drops – RED
  • Bempedoic acid – comments sought regarding a change to GREEN
  • Steroid eye drops (betamethasone 0.1%, dexamethasone 0.1%, prednisolone 0.03%, 0.1%, 0.5% & 1%, fluorometholone 0.1%) – GREEN (specialist initiation)
  • Rimegepant for preventing migraine – GREEN (specialist initiation) OR GREEN (specialist advice)
  • Semaglutide for overweight and obesity in young people aged 12-17 years – Do Not Prescribe.

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Friday 22nd September 2023. To take part, visit the consultations page.


Consultation: actions from July CRG meeting

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their July 2023 meeting. Actions in this consultation include:

  • Bulevirtide for chronic hepatitis D – add to formulary as RED
  • Esketamine for major depressive disorder in adults at imminent risk of suicide – update existing DNP listing to include this indication
  • Dapagliflozin for chronic heart failure with preserved or mildly reduced ejection fraction – add to formulary as GREEN (following specialist advice)
  • Upadacitinib for Crohn’s disease – add to formulary as RED
  • Deucravactinib for plaque psoriasis – add to formulary as RED
  • Emollient bath additives – update DNP listing to include reference to new NICE ‘do not do’ recommendation

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Tuesday 29th August 2023. To take part, visit the consultations page.


Consultation: actions from June CRG meeting

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their June 2023 meeting. Actions in this consultation include:

  • Hydrocortisone 0.5% ointment, and 2.5% cream and ointment – add to Do Not Prescribe list
  • Infliximab 120mg pre-filled syringe / pen and vedolizumab 108mg pre-filled syringe / pen – RED
  • Risankizumab for moderately to severely active Crohn’s disease – RED
  • Voclosporin with mycophenolate for lupus nephritis – RED
  • Difelikefalin for pruritus in haemodialysis – RED
  • Tranexamic acid injection – RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Friday 28th July 2023.


Consultation: actions from May CRG meeting

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their May 2023 meeting. Actions in this consultation include:

  • Fosfomycin 3g oral sachets for uncomplicated UTI in non-pregnant women – to be GREEN
  • Tezepelumab for severe asthma – to be RED

All links to MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Friday 23rd June 2023.


Consultation: actions from January 2023 meeting of CRG

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the January 2023 CRG meeting.

Actions in this consultation include:

  • Avatrombopag added to formulary as a RED drug for primary chronic immune thrombocytopenia.
  • Esketamine nasal spray for treatment-resistant depression added to the DNP list.

All links to MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Monday 6th March 2023.


Consultation: actions from December meeting of CRG

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the December 2022 CRG meeting.

Actions in this consultation include:

  • Donepezil, galantamine and rivastigmine for mild to moderate Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease: Green (specialist advice)
  • Cyclogest added to formulary as an option for vaginal micronised progesterone for prevention of miscarriage

All links to MHRA drug safety updates will be added to formulary as appropriate.

To take part in this consultation, visit the consultations page. The consultation period is open until 5pm on Thursday 26th January 2023.